GlassScriptPhysician profile
Charlsey Crawford
NPI 1528546462
$3,515.98
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,651 · 2022: $1,750 · 2023: $52.33 · 2024: $62.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $114.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.18 | 2022-2024 | |
| Biogen, INC. | $495.81 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $243.32 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $200.02 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $195.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $167.56 | 2021 | |
| Sk Life Science, INC. | $138.90 | 2021-2022 | |
| Alfasigma USA, INC. | $132.93 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $130.27 | 2021-2022 | |
| Harmony Biosciences LLC | $125.37 | 2022 | |
| Lundbeck LLC | $84.30 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $73.14 | 2021-2023 | Nuplazid |
| Amgen INC. | $71.66 | 2021-2022 | |
| Ucb, INC. | $69.88 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $69.26 | 2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $64.04 | 2021-2022 | |
| Lilly USA, LLC | $63.63 | 2021-2022 | |
| Pfizer INC. | $60.78 | 2021-2022 | |
| Eisai INC. | $49.84 | 2021 | |
| Neurocrine Biosciences, INC. | $45.68 | 2021-2022 | |
| Avion Pharmaceuticals | $45.44 | 2022 | |
| Kyowa Kirin, INC. | $44.27 | 2021-2022 | |
| Genzyme Corporation | $40.62 | 2021-2022 | |
| Neurelis, INC. | $39.65 | 2021 | |
| Allergan, INC. | $38.90 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $37.72 | 2021-2022 | |
| Tanabe Pharma America, INC. | $31.14 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $28.88 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $28.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $25.66 | 2022 | |
| Emd Serono, INC. | $21.91 | 2022 | |
| Sunovion Pharmaceuticals INC. | $21.78 | 2021 | |
| Grt US Holding, INC. | $19.62 | 2022 | |
| Zogenix INC. | $18.84 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.94 | 2022 | |
| Banner Life Sciences, LLC | $14.61 | 2022 | |
| Grifols USA, LLC | $12.40 | 2022 | |
| Endo Pharmaceuticals INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlsey Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.